J. Randolph Hecht, MD from UCLA Health is conducting a phase 3 clinical trial called STELLAR-303 to evaluate the efficacy and safety of a novel multi-kinase inhibitor (MKI) called XL092 in combination with atezolizumab, an immune checkpoint inhibitor (ICI), compared to regorafenib in patients with previously treated metastatic colorectal cancer (mCRC). The trial aims to … Continue reading Colorectal Cancer Treatment: The STELLAR-303 Phase 3 Trial of XL092 in Combination with Atezolizumab